CTIS2023-510089-28-00进行中（未招募）1 期
Combinatory ImmunoTherapy-2 (Com-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer
Oslo University Hospital HF0 个研究点目标入组 30 人开始时间: 2024年4月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Stage IV NSCLC with clinical indication of starting systemic treatment with immunotherapy alone or in combination with chemotherapy (first or later lines), Women of childbearing potential (WOCBP) should use a highly effective method during the treatment period and for at least 5 months after the last dose of immunotherapy to avoid pregnancy. Methods considered as highly effective birth control methods include combined (estrogen and progestogen containing) or progestogen-only hormonal contraception associated with inhibition of ovulation (oral, intravaginal, injectable, implantable or transdermal), intrauterine device (including hormone-releasing), male condom, bilateral tubal occlusion, vasectomised partner or sexual abstinence, Able to understand oral and written information and able to answer questionnaires, • Available core or excisional biopsy of a tumour lesion, • Measurable disease according to RECIST criteria (RECIST 1.1), • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, • Life expectancy > 3 months, • At least 1 tumour lesion suitable for radiotherapy treatment, Age >18 years, Written informed consent, Adequate organ function based on clinical examination and lab values (o Hb>9 g/dL o Neutrophils >1500 pr mm3 o Estimated creatinine clearance >40 mL/min o AST and ALT <2.5 x upper normal limit (if liver metastases: AST/ALT must be <5x upper normal limit) o Serum bilirubin < 1.5 x upper normal limit)
排除标准
- •Indication for radiotherapy other than stereotactic radiosurgery of brain metastases, Women who are not postmenopausal (postmenopausal defined as = 12 months of non-drug-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 2 weeks prior to initiation of study drug. Positive test is exclusion criterion., Known hypersensitivity to the immunotherapy regimen planned for the patient the investigational product, Live vaccine administered last 30 days, active infection requiring IV antibiotics, active viral hepatitis or HIV, Previous allogenic or organ transplant, Any reason why, in the opinion of the investigator, the patient should not participate, Pregnancy or lactation, Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 2 weeks prior to first administration of study drug., Disease suitable for curative salvage surgery, • Significant cardiac, pulmonary or other medical illness that would limit activity or survival, • Previous treatment with PD1/PDL-1 inhibitor, • Radiotherapy given within the last 4 weeks prior to inclusion, • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, • Patients with EGFR-mutation or ALK-translocation not previously treated with tyrosine kinase inhibitor, • Patients who test positive for hepatitis B, C or HIV, • Known larger active brain metastases that cannot be treated with stereotactic radiotherapy. Patients with stable/previously treated brain metastases can be included. Patients with several smaller brain metastases may be included if the larger metastases are treated with stereotactic radiotherapy, • Diagnosis of immunodeficiency or medical condition requiring high doses (>20 mg prednisolone daily) of systemic steroids or other forms of immunosuppressive therapy
研究者
相似试验
已完成
2 期
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer PatientsBreast CancerNCT02297698Cancer Insight, LLC100
进行中（未招募）
不适用
Pilot phase II study of a combined immunotherapy protocol based on oral vaccination and direct intratumoral injection of Salmonella Typhi Ty21a Vivotif in metastatic cutaneous melanoma patients. - NDMetastatic stage III e IV M1a melanomaMedDRA version: 6.1Level: PTClassification code 10042551EUCTR2005-005775-15-ITISTITUTO EUROPEO DI ONCOLOGIA43
进行中（未招募）
不适用
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .EUCTR2008-001421-34-DEniversity of Cologne, Sponsor-Quality Management16
进行中（未招募）
不适用
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL.EUCTR2008-001421-34-ATniversität zu Köln16
已完成
1 期
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLCMetastatic Non-small Cell Lung CancerNSCLCNCT03164772Ludwig Institute for Cancer Research61